Accueil > Products > Anticorps > Anticorps pour Cytométrie en Flux

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088) (HV974107)

Fiche technique Partager le produit Copier les informations

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)

Prix(USD) : $

Spécification :

50ug
100ug

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique

Aperçu

Numéro de catalogue	HV974107
Description	Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088) [SAA0088] (HV974107) is a human monoclonal antibody detecting B7-H1 in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications.
Reactivité des espèces	Human
Applications	FCM
Espèce hôte	Human
Isotype	IgG4, kappa
ID de clone	SAA0088
Clonalité	Monoclonal
Cible	B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274
Niveau d'endotoxines	Please contact with the lab for this information.
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q9NZQ7
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Contexte	Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi). 1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443 2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410 3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417 4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419 5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298 6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077 7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
Note	For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)

Reférences

Fiche technique

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088).pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : support@abinScience.com

Liste des distributeurs

Anti-Human CD274/PD-L1/B7-H1 Antibody (SAA0088)